COVID-19 Vaccines: Pakistan’s Perspective

COVID-19 Vaccines: Pakistan’s Perspective


  • Sidra Rahman Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
  • Misbahud Din Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
  • Sahrish Khan Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
  • Lubna Yar Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
  • Fatima Zia Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
  • Muhammad Idrees Centre of Excellence in Molecular Biology, University of the Punjab, Lahore-53700, Pakistan
  • Muhammad Ali Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan , Pakistan Academy of Sciences, Islamabad, Pakistan


COVID-19, Vaccine, New Variants, Pandemic, Efficacy, Mutations


The pandemic of COVID-19 has affected millions of individuals around the globe. Its impact on the world has made essential progress in the research sector to develop safe and effective vaccines. Several vaccines for COVID-19 have been made utilizing the SARS-CoV-2’s spike protein. Presently, Moderna’s COVID-19 vaccine, Pfizer-BioNTech COVID-19 vaccine, and Johnson & Johnson’s Janssen vaccine are approved and suggested by CDC to prevent the COVID-19. Five vaccines (till April 2021) have been approved by WHO on emergency basis which are AstraZeneca, Pfizer-BioNTech, Moderna, Sinopharm, and Johnson & Johnson. The Food and Drug Administration approve the scientific standard of drugs and vaccine such as their efficacy, safety, and quality. Currently, ambiguous information regarding COVID-19 vaccine are being circulated globally. During health crisis, rumours roll out and
generate fear, psychosis, and anxiety. On the other hand, the variants of SARS-CoV-2 are continuously emerging across the globe. Different platforms are being utilized for the development of whole virus-based vaccine, nucleic acid-based vaccine, and proteins sub-unit vaccine; all displayed good efficacy where few were further proceeded to clinical trials. The current article provide an overview on the COVID-19 vaccines, their efficacy, and discuss the possible reduction in vaccine efficacy due to the emergence of new variants. 


World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard (2020). (accessed 24 January 2021)

M. Din., H. Ali., M. Khan., A. Waris., S. Ullah., M. Kashif, and M. Ali. Impact of COVID‐19 on polio vaccination in Pakistan: a concise overview. Reviews in medical virology 31(4): e2190 (2020).

K. Dhama., K. Sharun., R. Tiwari., M. Dadar., Y. S. Malik., K. P. Singh, and W. Chaicumpa. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human vaccines & immunotherapeutics 16(6): 1232-1238 (2020).

Q. Gao., L. Bao., H. Mao., L. Wang., K. Xu., M. Yang, and Qin. C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369(6499): 77-81 (2020).

W. H. Chen., X. Tao., A. S. Agrawal., A. Algaissi., B. H. Peng., J. Pollet, and C. T. K. Tseng. Yeastexpressed SARS-CoV recombinant receptorbinding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine 38(47): 7533-7541 (2020).

N. van Doremalen., T. Lambe., A. Spencer., S. BelijRammerstorfer., J. N. Purushotham., J. R. Port, and V. J. Munster. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586(7830): 578-582 (2020).

F. C. Zhu., Y. H. Li., X. H. Guan., L. H. Hou., W. J. Wang., J. X. Li, and W. Chen. Safety, tolerability, and immunogenicity of a recombinant adenovirus type5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet 95(10240): 1845-1854 (2020).

D. F. Robbiani., C. Gaebler., F. Muecksch., J. C. Lorenzi., Z. Wang., A. Cho, and M. C. Nussenzweig. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584(7821): 437-442 (2020).

J. Yu., L. H. Tostanoski., L. Peter., N. B. Mercado., K. McMahan., S. H Mahrokhian, and D. H. Barouch. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369(6505): 806-811 (2020).

K. Dhama., K. Sharun., R. Tiwari., M. Dadar., Y. S. Malik., K. P. Singh, and W. Chaicumpa. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human vaccines & immunotherapeutics 16(6): 1232-1238 (2020).

Pharmaceutical Technology: Covid-19 Vaccination Tracker. Latest news, statistics, daily rates, and updates (2021) (accessed 27 May 2021)

WHO. Draft landscape of COVID-19 candidate vaccines. World Health Organisation (2020).

CDC: Different COVID-19 Vaccines (2021) (accessed 27 May 2021)

WHO: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process (2021).

N. Wang., J. Shang., S. Jiang, and L. Du. Subunit ,vaccines against emerging pathogenic human coronaviruses. Frontiers in microbiology 11: 298 (2020).

M. J. Mulligan., K. E. Lyke., N. Kitchin., J. Absalon., A. Gurtman., S. Lockhart, and K. U. Jansen. Phase 1/2 study to describe the safety and

immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. Nature 586(7830):589-593 (2020).

Tu. Y. F., Chien. C. S., Yarmishyn. A. A., Lin. Y. Y., Luo. Y. H., Lin. Y. T, and Chiou. S. H. A review of SARS-CoV-2 and the ongoing clinical trials. International journal of molecular sciences 21(7): 2657 (2020).

C. NCT04283461. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection. Clinical Trials. gov (2020).

moderna: Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus (2020) (2020).

Central of Disease Control and Prevention (2020). (accessed 24 January 2021)

COVID-19 Vaccine Policies & Guidance. (2021).

The News: /779104-russian-covid-19-vaccine-allowed-inpakistan (accessed 24 January 2021)

Cincinnati Children’s. Coronavirus (COVID-19) Vaccines | Myths and Truths (2020) (accessed 20 February 2021)

J. Wise. Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers British medical journal 373: n954 (2021).

World health Organization: Episode #24 - Vaccine myths vs science (2021). (accessed 5 February 2021)

Reuters: Fact check: RFID microchips will not be injected with the COVID-19 vaccine, altered video features Bill and Melinda Gates and Jack Ma (2020) (accessed 5 February 2021)

I. Ali. The covid-19 pandemic: Making sense of rumor and fear: Op-ed. Medical anthropology 39(5): 376-379 (2020).

U. A. Awan., A. A. Khattak., M. S. Afzal., N. Iqbal, and M. F. Nadeem. Emergence of SARS‐CoV‐2 Variant: A Wake‐Up Call for Pakistan’s

overburdened Healthcare System. Journal of Medical Virology. 93 (5): 2595-2598 (2021).

M. Chand. Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF). Public Health England (2020).

BBC NEWS: UK coronavirus variant spreading ‘rapidly’ through US, study finds (2021) (accessed 14 February 2021)

Wionews: Pakistan extends travel restrictions on six countries including UK till Feb 28 (accessed 15 February 2021)

NEWS.CGTN: China’s drug regulator accepts CanSinoBIO COVID-19 vaccine application (accessed 25 February 2021)

Fortune: It’s not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that’s 65% effective (2021). (accessed 14 February 2021)

news-medical life sciences: Study shows real-world effectiveness of Moderna and Pfizer/BioNtech vaccines (2021). (accessed 22 February 2021)

China Briefing: China’s COVID-19 Vaccine Development and Availability (2021). (accessed 14 February 2021)

BBC NEWS: Oxford-AZ vaccine ‘effective against dominant UK variant’ (2021). (accessed 15 February 2021)

CDC: Genomic Surveillance for SARSCoV-2 Variants (2021). (accessed 15 February 2021)

E. Callaway. Fast-spreading COVID variant can elude immune responses. Nature 589(7843): 500-501 (2021).

G. Salvatori., L. Luberto., M. Maffei., L. Aurisicchio., G. Roscilli., F. Palombo, and E. Marra. SARS-CoV-2 SPIKE PROTEIN: an optimal

immunological target for vaccines. Journal of translational medicine 18: 1-3 (2020).

C. K. Wibmer., F. Ayres., T. Hermanus., M. Madzivhandila., P. Kgagudi., B. E. Lambson, and P. L. Moore. SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine 27: 622–625 (2021).




How to Cite

Rahman, S., Din, M. ., Khan, . S., Yar, . L. ., Zia, . F. ., Idrees, M., & Ali, . M. (2021). COVID-19 Vaccines: Pakistan’s Perspective: COVID-19 Vaccines: Pakistan’s Perspective . Proceedings of the Pakistan Academy of Sciences: B. Life and Environmental Sciences, 58(S), 11–17. Retrieved from